Brand-New bioLIVE China in 2019
LEADING THE BIOPHARMACEUTICAL TRENDS IN AISA

In recent years, with the rapid development of cutting edge bio technologies and the mass emerge of new target drugs and cytotherapies, the biopharmaceutical industry is entering a blooming new age. In view of the global marketing size, the sales of biopharmaceutical drugs are expected to exceed 1/3 of the overall drug sales income. As per the statistics by InSight, the registrations of domestic bio drugs counted for 616 in year 2017, which exceeded the highest in the recent 5 years. As is predicted by Frost & Sullivan, the market size of China’s bio drugs will reach 326.9 billion RMB, with its increase rate ranking among the highest countries in the world.

In 2019, the brand new bioLIVE China will be launched, as an upgrade from the seven-year-old biopharmaceutical platform BioPh China. bioLIVE China 2019 will focus on life science & technology and innovative drugs, aiming to lead industrial trends and booster development in the biopharmaceutical area.

EXHIBITOR PROFILE
Biologics and New Therapies

Recombinant Protein

Polypeptide

Nucleic Acid

Vaccines

Plasma

Antibodies

Cell and Gene Therapy

Tumor Immunotherapy

Stem Cell & iPS

Bioprocessing, Manufacturing and Solutions

Cell Culture Media

Biological Reagents

Laboratory Consumables

Bioreactors

Bioseparation

Protein Purification

Bioprocessing

Software and Service

Biotechnology and R&D services

Molecular Biology

Cell Biology

Proteomics and Metabolomics

Biotechnology Service Platform

Detection Services

Biology Information Services

Drug R&D and Manufacturing

Clinical Research

2019 EXHIBITOR LIST (PARTIAL)

VISITOR PROFILE

Top 5 Departments

R & D

16.67%

Technician/Engineer

11.79%

Product Manager

7.64%

Extend Industry Connections with Industry Elites

A gathering of high-end pharmaceutical ecosystem with half of attendees having decision making power
Manager/Project Manager/Head of Department 30.09%
CEO/President/Board Member/General Manager 19.60%